Talphera (TLPH) Income from Continuing Operations (2010 - 2026)
Talphera (TLPH) recorded quarterly Income from Continuing Operations of 3779000.0 in Q1 2026, down 13.11% quarter-over-quarter from 3341000.0 in Q3 2025, and down 32.74% on a YoY basis from 5618179.11 in Q1 2025.
Talphera (TLPH) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Talphera's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 3779000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 32.74% year-over-year to 3779000.0; the TTM figure through Mar 2026 stood at 13577000.0 (down 5.09% YoY), while the FY2024 annual figure was 14573000.0, down 41.66% from the prior year.
- Income from Continuing Operations was 3779000.0 for Q1 2026 at Talphera, down from 3341000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 74315000.0 in Q2 2022 to a low of 5936000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 949187.5 across 5 years, with a median of 3803000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations jumped 854.39% in 2022, then tumbled 136.46% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 5936000.0 in 2022, then gained by 24.11% to 4505000.0 in 2023, then surged by 35.78% to 2893000.0 in 2024, then slipped by 15.49% to 3341000.0 in 2025, then retreated by 13.11% to 3779000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3779000.0 (Q1 2026), 3341000.0 (Q3 2025), and 3610000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Talphera | 56.42 Mn | 56.42 Mn | - | -3.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.78 Mn |
| Sep 30, 2025 | -3.34 Mn |
| Jun 30, 2025 | -3.61 Mn |
| Mar 31, 2025 | -2.85 Mn |
| Dec 31, 2024 | -2.89 Mn |
| Sep 30, 2024 | -3.35 Mn |
| Jun 30, 2024 | -3.83 Mn |
| Mar 31, 2024 | -4.02 Mn |
| Dec 31, 2023 | -4.51 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | -4.43 Mn |
| Mar 31, 2023 | -5.25 Mn |
| Dec 31, 2022 | -5.94 Mn |
| Sep 30, 2022 | -4.64 Mn |
| Jun 30, 2022 | 74.32 Mn |
| Mar 31, 2022 | -5.29 Mn |
| Dec 31, 2021 | -7.92 Mn |
| Sep 30, 2021 | -8.38 Mn |
| Jun 30, 2021 | -9.85 Mn |
| Mar 31, 2021 | -9.74 Mn |